{
    "Overall_score": {
        "Correlation": 9,
        "Sentiment": 7,
        "Importance": 8,
        "Impact": 7,
        "Duration": 6,
        "Virality": 5,
        "Source_Score": 8,
        "Specificity": 9,
        "Sector_Spread": 4,
        "Tech_Mentions": 2
    },
    "Each_item": [
        {
            "News_content": "RT @abbvie: $ABBV presents detailed SAPPHIRE-I data for an investigational regimen in treatment-naive GT1 #HCV patients at #EASL",
            "Correlation": 9,
            "Sentiment": 7,
            "Importance": 8,
            "Impact": 7,
            "Duration": 6,
            "Virality": 4,
            "Source_Score": 8,
            "Specificity": 9,
            "Sector_Spread": 3,
            "Tech_Mentions": 2
        },
        {
            "News_content": "RT @portefeuillefun: $ENTA. $ABBV to Present Detailed Phase III Results from SAPPHIRE-I and SAPPHIRE-II Studies in Chronic Hep C Patients",
            "Correlation": 8,
            "Sentiment": 7,
            "Importance": 8,
            "Impact": 7,
            "Duration": 6,
            "Virality": 5,
            "Source_Score": 7,
            "Specificity": 8,
            "Sector_Spread": 4,
            "Tech_Mentions": 2
        },
        {
            "News_content": "RT @abbvie: Results from $ABBV phase III program presented at #EASL for GT1 treatment-na√Øve/experienced #HCV patients",
            "Correlation": 9,
            "Sentiment": 7,
            "Importance": 8,
            "Impact": 7,
            "Duration": 6,
            "Virality": 4,
            "Source_Score": 8,
            "Specificity": 9,
            "Sector_Spread": 3,
            "Tech_Mentions": 2
        }
    ]
}